Deciphering myeloid (progenitor) cell function and communication in (tumor) tissues

Lei, X.

Citation

Lei, X. (2024, September 10). *Deciphering myeloid (progenitor) cell function and communication in (tumor) tissues*. Retrieved from https://hdl.handle.net/1887/4082521

Chapter

1

General Introduction and thesis outline

Myeloid cells that develop from hematopoietic precursors during a process called myelopoiesis, include granulocytes, monocytes, macrophages (MΦ), osteoclasts and dendritic cells (DC). Myeloid cells, in particular DC, play a crucial role in bridging innate immunity with adaptive immunity[1,2]. Emerging evidence indicates that beyond direct interaction with tumor cells or tumor stroma[3,4], the interactionn of myeloid cells with adaptive immune cells regulates cancer progression. Therefore, understanding how these cells and their precursors are regulated both locally and systemically is of great importance in the field of cancer immunology and immunotherapy.

Myelopoiesis and DC ontogeny

To maintain homeostasis of the mature blood system, strict regulation is required in processes controlling self-renewal, lineage specification, and differentiation of their precursors in the bone marrow (BM)[5,6]. Over the last decades, a classical model of cell differentiation was established for myelopoiesis at steady state in the adult individual. Following this model, the various myeloid lineage cells follow a hierarchical scheme starting with hematopoietic stem cells (HSC), followed by more dedicated multipotent progenitor (MPP), common myelopoietic progenitor (CMP)[7] and granulocyte/monocyte/ macrophage progenitor (GMP) which is also defined as granulocyte/monocyte/osteoclast/ DC progenitor (GMODP)[8], then unipotent progenitors such as the common monocyte progenitor (cMoP)[9] and common DC progenitor (CDP)[10]. The development of myeloid lineages is linked to distinct transcriptional factors (TF)[6,11], such as PU.1, and the CEBP and IRF families[2,6,12]. Notably, a continuum model has been proposed in recent years due to advances in single-cell (sc) technologies (Fig. 1). This model describes a progressive loss of multilineage differentiation potential of hematopoietic precursors at various developmental stages, suggesting that commitment to a restricted set of lineages can occur as early as the multipotent progenitor (MPP) stage, and continuously throughout hematopoiesis[13–15].

The DC, that is originally defined by its distinct morphology[16], is one of the cell types arising from myelopoiesis. DC subset identity is defined by ontogeny, combined with a certain level of tissue imprinting[11]. The traditional view is that three major DC subsets develop under homeostatic conditions: plasmacytoid (p)DC, classical DC type 2 (cDC2) and cDC1. The development of each of these DC lineages is controlled by distinct TF[6,11], such as *ZEB2* and *IRF8* for pDC, *IRF4* and *KLF4* for cDC2, and *BATF3* and *IRF8* for cDC1 (Fig. 1). These DC lineages are distinct from monocyte-derived DC

(moDC), that are derived from monocytes under inflammatory conditions[2,17,18]. The four main DC lineages can also be discerned by their key surface markers in combination with shared major histocompatibility class (MHC)-II expression. pDC express CD123, CD303, and CD304. cDC2 express CD1c and SIRPα. cDC1 express CD141, XCR1, and CLEC9A. moDC express CD14, CD206 and CD1a[19]. Recent studies have revealed remarkable homogeneity of cDC1 as a subset present in all healthy and diseased tissues analyzed, whereas cDC2 are found to exhibit heterogeneity[11,18,20]. Single cell (sc)RNA-sequencing (seq) analysis[17,18] identified a CD1c+ DC population expressing monocyte-related genes (i.e., *FCN1, CD14*, and *CD163*) alongside genes associated with classical cDC2 (i.e., *CD1c, FCER1A*, and *CLEC10A*). Cytlak *et al*.[20] have further demonstrated that the cDC2 subset can be discerned into CD1c+CD163- cDC2A and CD1c+CD163+ cDC2B subsets that develop along distinct hematopoietic trajectories. cDC2A arise from IRF8highCD123+ GMP together with pDC and cDC1, whereas cDC2B and monocytes derive from IRF8lowCD33+ GMP (Fig. 1).

Modulation and adaption of myelopoiesis is an integral part of an optimized immune response toward pathogens or sterile insults. During infection/inflammation, steady-state myelopoiesis undergoes a transition to emergency myelopoiesis by launching a unique hematopoietic response program that is aimed at greatly increasing myeloid cell output to meet the heightened demand[21,22]. This transition can be driven by pattern-recognition receptors (PRR) expressed by hematopoietic and non-hematopoietic cells in the bone marrow (BM) niches and affected tissues. These stress sensors induce the production of proinflammatory cytokines[21–23] and chemokines[24–26]. Myeloid progenitor cells also alter their expression of cytokine[27] and chemokine[26,28,29] receptors. Collectively, these effects lead to increased myeloid cell production in the BM, and the migration of both myeloid progenitors and differentiated myeloid cells into the affected tissues. Evidence also suggests enhanced proliferation and differentiation of myeloid progenitor cells *in situ*[26,30]. Of note, despite the obvious beneficial effects of inflammation-induced activation of the hematopoietic system, increasing evidence also points to detrimental effects of chronic inflammatory stress[31–33], such as cancer[34] on the functions of hematopoietic progenitor cells. Apart from external stress, somatic driver mutations can also alter the functions of myeloid progenitor cells. This can lead to the clonal dominance of a subset of myeloid progenitors and their progenies, a process referred to as clonal myelopoiesis. Clonal myelopoiesis has been linked to a proinflammatory phenotype of hematopoietic cells, immune dysfunction and myeloid neoplasia[35,36]. Although several studies demonstrated the involvement of NLRP3 inflammasome[37] and inflammatory cytokines[36], the

mechanistic connections between clonal myelopoiesis and functional dysregulation of myeloid progenitor cells remain active subjects of investigation.


Fig. 1. Modified model of myelopoiesis and DC ontogeny. Illustration depicting continuum model of myelopoiesis in the adult that proposes lineage precommitment as early as the MPP stage and heterogeneity in downstream progenitor cells. Shown are ontogeny, key transcription factors and functions of pDC, cDC1, CD163- cDC2A, CD163+ cDC2B and moDC. Abbreviations: HSC, hematopoietic stem cell; MPP, multipotent progenitor; CMP, common myelopoietic progenitor; GMP, granulocyte/monocyte/macrophage progenitor; GMODP, granulocyte/monocyte/osteoclast/ DC progenitor; CDP, common DC progenitor; cMoP, common monocyte precursor; moDC, monocyte-derived DC.

DC functions and their roles in tumor immunity

DC are professional antigen-presenting cells (APC) and function as the sentinels of the immune system. Concomitant to antigen sampling, DC can sense various entities such as microbes, infected- and damaged/dead cells via PRR such as Toll-like receptors, which leads to their activation[38]. The key function of DC is the regulation of antigen-specific T-cell responses. DC can present exogenous antigens via MHC-I to CD8+ T-cells in a

process termed cross-presentation, and via MHC-II to CD4[+] T-cells. Apart from triggering the T-cell receptor (TCR) by presenting its ligand, peptide/MHC complex, DC can also express co-stimulatory molecules including CD80, CD86 and CD70, and produce cytokines including IL-12 and IL-15 to regulate T-cell activation, proliferation and differentiation[39,40]. Additionally, DC also express co-inhibitory molecules such as PD-L1 and PD-L2[41] to control the T-cell response and to balance between tolerance and immunity. Thus, DC serve not only as central coordinators of the immune responses against threats, but also as regulators of immune homeostasis at steady-state. Notably, DC that exhibit a "semi-mature" state characterized by low expression of MHC-II and co-stimulatory molecules[42,43], decreased expression of proinflammatory cytokines, along with tolerogenic attributes[44,45], are designated as tolerogenic, as opposed to immunogenic DC.

Each DC subset also possesses its unique functional properties. Although pDC are major sources of type I interferon (IFN-I) especially upon viral infection, they are generally considered to be suppressive in the tumor micro-environment (TME) Tumor-infiltrated pDC have impaired IFN-I production[46] and can induce regulatory T-cell (Treg) activation via ICOS-ligand(L)[47] or IDO[48]. Both cDC2 and cDC1 can be subdivided into migratory and lymph node (LN) resident subsets. Evidence suggests that resident cDC can receive antigens from the migratory population[49]. cDC2 can induce polarization of naïve CD4[+] T-cells into T helper (Th)1, Th2 or Th17 cells upon exposure to extracellular pathogens[2,50]. Recent studies have also indicated that cDC2 can present soluble antigens to CD8[+] T-cells in the lymph nodes (LN)[51,52], as well as provide co-stimulation in the TME to support further effector differentiation of stem-like T-cells that have been (semi)primed in tumor draining lymph nodes (tdLN)[53]. The role of cDC2 in cancer immunology is less established, partly due to their high degree of heterogeneity[54]. cDC1 are specialized in cross-presenting cell-associated antigens and relaying CD4[+] T-cell help to CD8[+] T-cells[51,52,55]. The cDC1 subset is required for CD8[+] T-cell mediated spontaneous tumor regression, and enhances survival benefits in various preclinical models employing adoptive T-cell transfer or immune checkpoint blockade (ICB) therapy[56–58]. The importance of cDC1 for anti-tumor immunity in part reflects their ability to acquire antigens from tumor cells and transport these tumor antigens to tdLN to initiate *de novo* T-cell responses[49,59]. Moreover, emerging evidence suggests that cDC1 regulate anti-tumor immunity directly within the TME, by *in situ* tumor antigen presentation[60–62], as well as local provision of chemokines[61,63], cytokines[64] and co-stimulatory signals[53,65]. Notably, multiple transcriptome-based immune-cell profiling studies of the TME have recently revealed a tumor-infiltrating "mature" DC state, which

is present exclusively in tumor tissues[66–68]. Both tumor-infiltrating cDC1 and cDC2 are shown to acquire this conserved "mature" DC program characterized by the expression of immune stimulatory-, regulatory, migratory and antigen processing genes[52,54,66–68]. Importantly, these "mature" DC are enriched within "immune" niches and associated with improved prognosis[52,62,68–70]. Finally, the exact functions of moDC *in vivo* is not yet fully elucidated, but they are not critical for T cell priming (ref). However, due to their ease of generation in large-scale *in vitro*, moDC have been utilized in numerous anti-cancer DC vaccine trials[71,72].

(Tumor-reactive) T-cell (cross)priming and differentiation

The priming of naive T-cells is initiated by a primary recognition of specific peptide/ MHC complexes in lymphoid tissues. This process consists of a series of biophysical, biochemical, metabolic and epigenetic changes that lead to clonal expansion of activated T cells and their differentiation into effector cells and/or long-lived memory cells. According to the paradigm, antigen-specific T-cell priming in the LN occurs in three distinct phases[73,74]. In phase I, T-cells that recognize antigen engage in brief contacts with DC, resulting in the upregulated expression of adhesion molecule CD69. In phase II, these T-cells decrease their motility and form synapses with DC where antigen, co-stimulation and cytokine signals are provided. In phase III, T-cells restore their motility and begin to proliferate and differentiate.

Antigen cross-presentation, a process by which exogenous antigens are taken up by DC and presented on MHC-I[75], is the foundation of successful CD8$^+$ T-cell cross-priming. TCR signals and environmental cues such as co-stimulatory signals and cytokines influence CD8$^+$ T-cell activation and differentiation. Apart from effector and memory differentiation, a distinct trajectory termed the "exhaustion" pathway[76,77] is also recognized in cancer and chronic infection. It is characterized by progressive loss of cytotoxic effector function and acquisition of inhibitory receptors such as PD-1 and TIM-3, driven by persistent antigen exposure. Notably, a stem-like memory stage of CD8$^+$ T-cell differentiation characterized by expression of TCF-1 and intermediate levels of PD-1 has recently been discovered both in both the tdLN and the TME[78–80]. The stem-like cell state is associated with proliferative capacity, self-renewal and long-term persistence, and is considered as the starting point of the "exhaustion" trajectory[76,77,81,82]. Importantly, increasing evidence[78,83] supports the association between stem-like CD8$^+$ T-cells and efficacy of ICB, positioning them as promising targets for cancer immunotherapies.

As for CD8[+] T-cells, clonal expansion and T helper (Th) differentiation of CD4[+] T cells rely on the strength and duration of peptide/MHC-II–TCR interactions, co-stimulation[84], and cytokine milieu[85]. In addition, other environmental factors, such as metabolic changes[86] and microbiome[87], may alter the states of CD4[+] Th cell subsets and their effector functions. Although the concept of "exhaustion" has been described for CD4[+] T-cells in the classical mouse model of chronic infection[88], the differentiation trajectory leading to this state and its clinical implication have only recently gained attention in cancer research[81,89,90]. Tumor-reactive PD-1[+]CXCL13[+]CD4[+] T-cells are heterogenous and are recently characterized by an expression profile previously assigned to either proliferating cells (i.e., *THYM, TOP2A*), CD4[+] T follicular helper (Tfh) cells (i.e., *TCF7, BCL6, CXCR5*), or "exhausted" cells (i.e., *HAVCR2, LAG3*)[90,91]. Notably, Tfh cells exhibit a transcriptional profile closely resembling that of stem-like CD8[+] T-cells[92], and a gradual transition process may exist from classical *IL21*[+] Tfh to *IFNG*[+] Tfh/Th1[90]. Consequently, it is likely that there is a continuum in the differentiation spectrum of CD4[+] T-cells in these states, mirroring the differentiation spectrum of their CD8[+] T-cell counterparts.

CD4[+] T-cell "help"

Although cDC are specialized in antigen processing and (cross)presentation, they alone are sometimes not enough to prime efficient CD8[+] T-cell responses, such as during tumor progression. The concept of CD4[+] T-cell "help" in enhancing CTL responses dates back to the 1970s[93,94]. Initially, cytokine secretion such as IL-2 by CD4[+] T-cells[95] was considered as a major mechanism. Later, the role of DC in CD4[+] T-cell "help" (DC licensing) was discovered[96,97]. Only recently, the cDC1 was pinpointed as the DC type relaying CD4[+] T-cell "help" for the generation of CTL responses against cell-associated antigens in the context of cancer[51,52]. Currently, cognate DC licensing via the CD40-CD40 ligand (L) axis[51,97,98] and its downstream CD70-CD27 axis[99,100] are considered the primary mechanisms of "help", although there is some evidence indicating that non-cognate DC licensing can occur[101]. Subsequently, "helped" cDC1 increase the expression of co-stimulatory molecules, cytokines, and anti-apoptotic molecules (e.g., Bcl-xL)[52,102]. Thus optimized "helped/ licensed" cDC1 can instruct optimal clonal expansion, effector and memory differentiation of the CD8[+] T-cells[51,52,99]. Furthermore, given the evidence linking metabolic programming and epigenetic modifications to DC functions[103–105], it is reasonable to speculate that CD4[+] T-cell "help" may modify these processes in cDC1,

although direct evidence remains limited.

The timing and location of CD4[+] T-cell "help" have been long-standing areas of interest. T-cell priming is the resultant of sequential interactions, guided by chemokines, with different DC types in lymphoid tissues. A two-step priming model (Fig. 2A) has been established based on intravital imaging to outline this process[40]. Initially, CD4[+] and CD8[+] T-cells are activated independently and asynchronously by migratory cDC2 and cDC1 respectively[106,107]. In a subsequent priming step, CD4[+] T-cells deliver the "help" signal through interactions with the same LN-resident cDC1, which also prime CD8[+] T-cells via cross-dressing[108] or cross-presentation[106,109]. Notably, recent studies have underscored the significance of migratory cDC1 in early CD4[+] T-cell priming in the secondary lymphoid organs[51], particularly in response to cell-associated tumor antigens. Thus a modified model[110] (Fig. 2B) has been recently proposed, wherein either migratory or LN-resident cDC1 can serve as the platforms for CD4[+] T-cell "help" in secondary lymphoid organs. It is likely that CD4[+] T-cells are activated first, enabling cDC1 to transmit "help" signals to CD8[+] T-cells. So far there is insufficient evidence supporting the capacity of LN-resident cDC1 to initiate CD4[+] T-cell priming (Fig. 2C). Nevertheless, these recent findings do not exclude the possibility that cDC2 serve as APC for CD4[+] T-cells[111,112]. Interestingly, increasing evidence also suggest that cDC, PD-1[+]CXCL13[+]CD4[+]Th cells and PD-1[+](TCF1[+])CD8[+] T-cells form close interactions in specific tumor niches (e.g., tertiary lymphoid structures (TLS), stem-immunity hub)[62,69,70,113], and CD8[+] T-cell effector differentiation happens not only in the tdLN but also in the TME[53,62]. Thus, a scenario in which the transmission of "help" by cDC1 can also take place in certain tumor niches has also been proposed[52].

Despite the absence of MHC-II on many tumors, the requirement for CD4[+] T-cells in cancer immunotherapy is increasingly appreciated[91,114,115]. The ability of CD4[+] T-cells to interact with MHC-II[+] DC (DC licensing) is crucial for persistent anti-tumor CD8[+] T-cell responses both in adoptive cell transfer[116] and cancer vaccine[115] settings. Studies using single-cell transcriptomics have identified transcriptional signatures of tumor-specific CD4[+] T-cells in the TME, and revealed a positive correlation between the presence of tumor-specific CD4[+] T-cells and tumor-specific CD8[+] T-cells and DC activation in the TME, as well as with patient survival[81,91]. Therefore, successful targeting of tumor-specific CD4[+] T-cells may provide a multifaceted attack on MHC-II negative cancer by supporting the activation of DC, which in turn promote the priming and functions of a diverse CD8[+] T-cell response to multiple tumor antigens.

Fig. 2. Model of CD4$^+$ T-cell licensing of cDC1 to induce CTL responses. (A) Migratory cDC2 can activate CD4$^+$ T-cells. Migratory cDC1 can transfer antigens to LN-resident cDC1. Subsequently, CD4$^+$ T-cells deliver the "help" signal through interactions with the same LN-resident cDC1 to (cross)prime efficient CTL responses. (B) Migratory cDC1 have the capacity to activate CD4$^+$ T-cells. Subsequently, "help" signals from CD4$^+$ T-cells are transmitted via the same DC to (cross)prime efficient cytotoxic CD8$^+$ T-lymphocyte (CTL) responses. (C) Migratory cDC1 can transfer antigens to LN-resident cDC1. It is possible that LN-resident cDC1 can also prime CD4$^+$ T-cells, although evidence is insufficient (dotted line with question mark). After CD4$^+$ T-cell activation, "help" signals are transmitted via the same DC to (cross)prime efficient CTL responses.

Description of the chapters in this thesis

The role of DC in CD4$^+$ T-cell "help" for anti-tumor CTL responses was discovered in 1990s. Since then, ample mouse studies have been conducted aiming to discover the mechanism of the "help" signals. In **chapter 2**, I delve into the molecular mechanisms of CD4$^+$ T-cell "help" as a critical signal that can successfully activate human cDC1 and describe the clinical significance of cDC1 licensing in human cancers.

So far, the mechanism of CD4$^+$ T-cell "help" to cDC1 is largely attributed to CD40/CD40L axis based on mouse studies. However, some studies argue that other mechanisms[51,117,118] may also be involved. In **chapter 3**, I explore the role of type I interferon (IFN-I) signaling as part of cDC1 licensing machinery, and identify tumor-infiltrating Ki67$^+$CXCL13$^+$CD4$^+$ T-cells as IFN-I producers in the context of help delivery to cDC1 in the tumor.

With the intention to employ the knowledge of DC biology in cancer treatments, in **chapter 4,** I summarize the findings made by us and others regarding tumor-infiltrating DC states and immune checkpoints targeting DC for antibody-based modulation in cancer.

As a continuation of chapter 4, in **chapter 5**, I explore the potential use of human cDC1-like cells generated *in vitro* from blood-derived myeloid progenitors to facilitate the development of adoptive T-cell transfer therapies.

As an integral component of my exploration into myeloid cell biology, the focus of chapters 6 and 7 is shifted to myeloid progenitors and myelopoiesis. In **chapter 6**, I investigate how myeloid progenitors respond to local inflammation within the context of toll-like receptor (TLR)5 stimulation and delineate the clinical implication of such response. In **chapter 7**, I describe our effort to identify the driver mutation-carrying myeloid progenitors among both high- and low-risk patients with Langerhans cell histiocytosis, leveraging our ability in generating a substantial number of progeny from myeloid progenitor cells *in vitro*.

References

1. Steinman, R. M. Decisions About Dendritic Cells: Past, Present, and Future. *Annu Rev Immunol* **30**, 1–22 (2012).

2. Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting. *Annu Rev Immunol* **31**, 563–604 (2013).

3. Broz, M. L. & Krummel, M. F. The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection. *Cancer Immunol Res* **3**, 313–319 (2015).

4. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* **12**, 253–268 (2012).

5. Orkin, S. H. Diversification of haematopoietic stem cells to specific lineages. *Nat Rev Genet* **1**, 57–64 (2000).

6. Murphy, T. L. *et al.* Transcriptional Control of Dendritic Cell Development. *Annu Rev Immunol* **34**, 93–119 (2016).

7. Doulatov, S., Notta, F., Laurenti, E. & Dick, J. E. Hematopoiesis: A Human Perspective. *Cell Stem Cell* **10**, 120–136 (2012).

8. Xiao, Y. *et al.* Identification of the Common Origins of Osteoclasts, Macrophages, and Dendritic Cells in Human Hematopoiesis. *Stem Cell Reports* **4**, 984–994 (2015).

9. Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. *Nat Rev Immunol* **14**, 392–404 (2014).

10. Liu, K. & Nussenzweig, M. C. Origin and development of dendritic cells. *Immunol Rev* **234**, 45–54 (2010).

11. Segura, E. Human dendritic cell subsets: An updated view of their ontogeny and functional specialization. *Eur J Immunol* **52**, 1759–1767 (2022).

12. Rosenbauer, F. & Tenen, D. G. Transcription factors in myeloid development: balancing differentiation with transformation. *Nat Rev Immunol* **7**, 105–117 (2007).

13. Notta, F. *et al.* Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. *Science (1979)* **351**, (2016).

14. Laurenti, E. & Göttgens, B. From haematopoietic stem cells to complex differentiation landscapes. *Nature* **553**, 418–426 (2018).

15. Bassler, K., Schulte-Schrepping, J., Warnat-Herresthal, S., Aschenbrenner, A. C. & Schultze, J. L. The Myeloid Cell Compartment—Cell by Cell. *Annu Rev Immunol* **37**, 269–293 (2019).

16. Steinman, R. M. & Cohn, Z. A. IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE. *J Exp Med* **137**, 1142–1162 (1973).

17. Dutertre, C.-A. *et al.* Single-Cell Analysis of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating Inflammatory Dendritic Cells. *Immunity* **51**, 573-589.e8 (2019).

18. Villani, A.-C. *et al.* Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science (1979)* **356**, eaah4573 (2017).

19. Durand, M. & Segura, E. The known unknowns of the human dendritic cell network. *Front Immunol* **6**, (2015).

20. Cytlak, U. *et al.* Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans. *Immunity* **53**, (2020).

21. Boettcher, S. & Manz, M. G. Regulation of Inflammation- and Infection-Driven Hematopoiesis. *Trends Immunol* **38**, 345–357 (2017).

22. Schultze, J. L., Mass, E. & Schlitzer, A. Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation. *Immunity* **50**, 288–301 (2019).

23. Chavakis, T., Mitroulis, I. & Hajishengallis, G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. *Nat Immunol* **20**, 802–811 (2019).

24. Sadek, M. I., Sada, E., Toossi, Z., Schwander, S. K. & Rich, E. A. Chemokines Induced by Infection of Mononuclear Phagocytes with Mycobacteria and Present in Lung Alveoli during Active Pulmonary Tuberculosis. *Am J Respir Cell Mol Biol* **19**, 513–521 (1998).

25. Clark, J. G., Kim, K.-H., Basom, R. S. & Gharib, S. A. Plasticity of Airway Epithelial Cell Transcriptome in Response to Flagellin. *PLoS One* **10**, e0115486 (2015).

26. Lei, X. *et al.* Flagellin/TLR5 Stimulate Myeloid Progenitors to Enter Lung Tissue and to Locally Differentiate Into Macrophages. *Front Immunol* **12**, (2021).

27. Mitroulis, I. *et al.* Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. *Cell* **172**, 147-161.e12 (2018).

28. Pereira da Costa, M. *et al.* Interplay between CXCR4 and CCR2 regulates bone marrow exit of dendritic cell progenitors. *Cell Rep* **42**, 112881 (2023).

29. Cabeza-Cabrerizo, M. *et al.* Recruitment of dendritic cell progenitors to foci of influenza A virus infection sustains immunity. *Sci Immunol* **6**, (2021).

30. Norris, B. A. & Ernst, J. D. Mononuclear cell dynamics in M. tuberculosis infection provide opportunities for therapeutic intervention. *PLoS Pathog* **14**, e1007154 (2018).

31. Pietras, E. M. *et al.* Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. *Nat Cell Biol* **18**, 607–618 (2016).

32. Essers, M. A. G. *et al.* IFNα activates dormant haematopoietic stem cells in vivo. *Nature* **458**, 904–908 (2009).

33. Sato, T. *et al.* Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion. *Nat Med* **15**, 696–700 (2009).

34. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. *Nature* **541**, 321–330 (2017).

35. von Bonin, M. *et al.* Clonal hematopoiesis and its emerging effects on cellular therapies. *Leukemia* **35**, 2752–2758 (2021).

36. Belizaire, R., Wong, W. J., Robinette, M. L. & Ebert, B. L. Clonal haematopoiesis and dysregulation of the immune system. *Nat Rev Immunol* **23**, 595–610 (2023).

37. Fuster, J. J. *et al.* Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science (1979)* **355**, 842–847 (2017).

38. Pulendran, B. The Varieties of Immunological Experience: Of Pathogens, Stress, and Dendritic Cells. *Annu Rev Immunol* **33**, 563–606 (2015).

39. Chen, D. S. & Mellman, I. Oncology Meets Immunology: The Cancer-Immunity Cycle. *Immunity* **39**, 1–10 (2013).

40. Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M. & Kastenmüller, W. CD4+ T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* **18**, (2018).

41. Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. *Nat Rev Immunol* **18**, 153–167 (2018).

42. Lutz, M. B. & Schuler, G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? *Trends Immunol* **23**, 445–449 (2002).

43. Iberg, C. A., Jones, A. & Hawiger, D. Dendritic Cells As Inducers of Peripheral Tolerance. *Trends Immunol* **38**, 793–804 (2017).

44. Comi, M. *et al.* Coexpression of CD163 and CD141 identifies human circulating IL-10-producing dendritic cells (DC-10). *Cell Mol Immunol* **17**, 95–107 (2020).

45. Maldonado, R. A. & von Andrian, U. H. How Tolerogenic Dendritic Cells Induce Regulatory T Cells. in 111–165 (2010). doi:10.1016/B978-0-12-380995-7.00004-5.

46. Sisirak, V. *et al.* Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. *Cancer Res* **72**, 5188–5197 (2012).

47. Ito, T. *et al.* Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand. *J Exp Med* **204**, 105–115 (2007).

48. Chen, W., Liang, X., Peterson, A. J., Munn, D. H. & Blazar, B. R. The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation. *The Journal of Immunology* **181**, 5396–5404 (2008).

49. Ruhland, M. K. *et al.* Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells. *Cancer Cell* **37**, 786-799.e5 (2020).

50. Durand, M. *et al.* Human lymphoid organ cDC2 and macrophages play complementary roles in T follicular helper responses. *Journal of Experimental Medicine* **216**, 1561–1581 (2019).

51. Ferris, S. T. *et al.* cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. *Nature* **584**, 624–629 (2020).

52. Lei, X. *et al.* CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment. *Nat Commun* **14**, 217 (2023).

53. Prokhnevska, N. *et al.* CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. *Immunity* **56**, 107-124.e5 (2023).

54. Cheng, S. *et al.* A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. *Cell* **184**, 792-809.e23 (2021).

55. Hildner, K. *et al. Batf3* Deficiency Reveals a Critical Role for CD8α⁺ Dendritic Cells in Cytotoxic T Cell Immunity. *Science (1979)* **322**, 1097–1100 (2008).

56. Bowman-Kirigin, J. A. *et al.* The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain. *Cancer Immunol Res* **11**, 20–37 (2023).

57. Oh, S. A. *et al.* PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. *Nat Cancer* **1**, 681–691 (2020).

58. Salmon, H. *et al.* Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. *Immunity* **44**, (2016).

59. Roberts, E. W. *et al.* Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. *Cancer Cell* **30**, 324–336 (2016).

60. Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. *Nat Rev Immunol* **14**, 447–462 (2014).

61. Meiser, P. *et al.* A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer Cell* **41**, 1498-1515.e10 (2023).

62. Magen, A. *et al.* Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. *Nat Med* **29**, 1389–1399 (2023).

63. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. *Cancer Cell* **31**, 711-723.e4 (2017).

64. Garris, C. S. *et al.* Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. *Immunity* **49**, 1148-1161.e7 (2018).

65. Duraiswamy, J. *et al.* Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. *Cancer Cell* **39**, 1623-1642.e20 (2021).

66. Maier, B. *et al.* A conserved dendritic-cell regulatory program limits antitumour immunity. *Nature* **580**, (2020).

67. Gerhard, G. M., Bill, R., Messemaker, M., Klein, A. M. & Pittet, M. J. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. *Journal of Experimental Medicine* vol. 218 Preprint at https://doi.org/10.1084/JEM.20200264 (2021).

68. Luca, B. A. *et al.* Atlas of clinically distinct cell states and ecosystems across human solid tumors. *Cell* **184**, 5482-5496.e28 (2021).

69. Chen, J. H. *et al.* Spatial analysis of human lung cancer reveals organized immune hubs enriched for 1 stem-like CD8 T cells and associated with immunotherapy response 2 3. *BioRxiv* (2023) doi:10.1101/2023.04.04.535379.

70. Cohen, M. *et al.* The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. *Nat Cancer* **3**, 303–317 (2022).

71. Collin, M. & Bigley, V. Human dendritic cell subsets: an update. *Immunology* **154**, 3–20 (2018).

72. Kantoff, P. W. *et al.* Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. *New England Journal of Medicine* **363**, 411–422 (2010).

73. Mempel, T. R., Henrickson, S. E. & von Andrian, U. H. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. *Nature* **427**, 154–159 (2004).

74. Bousso, P. & Robey, E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. *Nat Immunol* **4**, 579–585 (2003).

75. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. *J Exp Med* **143**, 1283–1288 (1976).

76. van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. *Nat Rev Cancer* **20**, 218–232 (2020).

77. Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in cancer. *Nat Rev Immunol* **22**, 209–223 (2022).

78. Siddiqui, I. *et al.* Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. *Immunity* **50**, 195-211.e10 (2019).

79. Kurtulus, S. *et al.* Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1− CD8+ Tumor-Infiltrating T Cells. *Immunity* **50**, 181-194.e6 (2019).

80. Brummelman, J. *et al.* High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. *Journal of Experimental Medicine* **215**, 2520–2535 (2018).

81. Oliveira, G. *et al.* Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. *Nature* **596**, 119–125 (2021).

82. Pritykin, Y. *et al.* A unified atlas of CD8 T cell dysfunctional states in cancer and infection. *Mol Cell* **81**, 2477-2493.e10 (2021).

83. Sade-Feldman, M. *et al.* Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell* **175**, 998-1013.e20 (2018).

84. van Panhuys, N. TCR Signal Strength Alters T–DC Activation and Interaction Times and Directs the Outcome of Differentiation. *Front Immunol* **7**, (2016).

85. Hilligan, K. L. & Ronchese, F. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. *Cell Mol Immunol* **17**, 587–599 (2020).

86. Zhou, L., Chong, M. M. W. & Littman, D. R. Plasticity of CD4+ T Cell Lineage Differentiation. *Immunity* **30**, 646–655 (2009).

87. Kiner, E. *et al.* Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes. *Nat Immunol* **22**, 216–228 (2021).

88. Crawford, A. *et al.* Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection. *Immunity* **40**, 289–302 (2014).

89. Miggelbrink, A. M. *et al.* CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer? *Clinical Cancer Research* **27**, 5742–5752 (2021).

90. Zheng, L. *et al.* Pan-cancer single-cell landscape of tumor-infiltrating T cells. *Science (1979)* **374**, (2021).

91. Veatch, J. R. *et al.* Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. *Cancer Cell* **40**, 393-409.e9 (2022).

92. Im, S. J. *et al.* Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature* **537**, 417–421 (2016).

93. von Boehmer, H., Haas, W. & Jerne, N. K. Major histocompatibility complex-linked immune-responsiveness is acquired by lymphocytes of low-responder mice differentiating in thymus of high-responder mice. *Proceedings of the National Academy of Sciences* **75**, 2439–2442 (1978).

94. Keene, J.-A. & Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. *J Exp Med* **155**, 768–782 (1982).

95. Fearon, E. R. *et al.* Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. *Cell* **60**, 397–403 (1990).

96. Bennett, S. R. M., Carbone, F. R., Karamalis, F., Miller, J. F. A. P. & Heath, W. R. Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help. *J Exp Med* **186**, 65–70 (1997).

97. Bennett, S. R. M. *et al.* Help for cytotoxic-T-cell responses is mediated by CD40 signalling. *Nature* **393**, 478–480 (1998).

98. Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. *Nature* **393**, 480–483 (1998).

99. Ahrends, T. *et al.* CD4+T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. *Immunity* **47**, 848-861.e5 (2017).

100. Feau, S. *et al.* The CD4[+] T-cell help signal is transmitted from APC to CD8[+] T-cells via CD27-CD70 interactions. *Nat Commun* **3**, (2012).

101. Pasqual, G. *et al.* Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling. *Nature* **553**, 496–500 (2018).

102. Wu, R. *et al.* Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. *Nat Immunol* **23**, 1536–1550 (2022).

103. Adamik, J. *et al.* Distinct metabolic states guide maturation of inflammatory and tolerogenic dendritic cells. *Nat Commun* **13**, 5184 (2022).

104. Shi, L. *et al.* TSC1/mTOR-controlled metabolic–epigenetic cross talk underpins DC control of CD8+ T-cell homeostasis. *PLoS Biol* **17**, e3000420 (2019).

105. Eastman, A. J. *et al.* Epigenetic stabilization of DC and DC precursor classical activation by TNFα contributes to protective T cell polarization. *Sci Adv* **5**, (2019).

106. Hor, J. L. *et al.* Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection. *Immunity* **43**, 554–565 (2015).

107. Kitano, M. *et al.* Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. *Proceedings of the National Academy of Sciences* **113**, 1044–1049 (2016).

108. Wakim, L. M. & Bevan, M. J. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. *Nature* **471**, 629–632 (2011).

109. Eickhoff, S. *et al.* Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions. *Cell* **162**, 1322–1337 (2015).

110. Murphy, T. L. & Murphy, K. M. Dendritic cells in cancer immunology. *Cell Mol Immunol* **19**, 3–13 (2022).

111. Williams, J. W. *et al.* Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. *Nat Commun* **4**, 2990 (2013).

112. Tatsumi, N., Codrington, A. L., El-Fenej, J., Phondge, V. & Kumamoto, Y. Effective CD4 T cell priming requires repertoire scanning by CD301b[+] migratory cDC2 cells upon lymph node entry. *Sci Immunol* **6**, (2021).

113. Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. *Nat Rev Cancer* **19**, 307–325 (2019).

114. Speiser, D. E., Chijioke, O., Schaeuble, K. & Münz, C. CD4+ T cells in cancer. *Nat Cancer* **4**, 317–329 (2023).

115. Alspach, E. *et al.* MHC-II neoantigens shape tumour immunity and response to immunotherapy. *Nature* **574**, 696–701 (2019).

116. Brightman, S. E. *et al.* Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors. *Nat Immunol* **24**, 1345–1357 (2023).

117. Bachmann, M. F. *et al.* Cutting Edge: Distinct Roles for T Help and CD40/CD40 Ligand in Regulating Differentiation of Proliferation-Competent Memory CD8+ T Cells. *The Journal of Immunology* **173**, 2217–2221 (2004).

118. Greyer, M. *et al.* T Cell Help Amplifies Innate Signals in CD8(+) DCs for Optimal CD8(+) T Cell Priming. *Cell Rep* **14**, (2016).

1